Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools by Nafiseh Nafissi & Marianna Foldvari
REVIEW
published: 14 October 2015
doi: 10.3389/fnins.2015.00355
Frontiers in Neuroscience | www.frontiersin.org 1 October 2015 | Volume 9 | Article 355
Edited by:
Ioan Opris,
Wake Forest University School of
Medicine, USA
Reviewed by:
Hun-Kuk Park,
Kyung Hee University, South Korea
Hari S. Sharma,
Uppsala University, Sweden
*Correspondence:
Marianna Foldvari,
School of Pharmacy and Waterloo
Institute of Nanotechnology, University
of Waterloo, 200 University Avenue
West, Waterloo, ON N2L 3G1,
Canada
foldvari@uwaterloo.ca
Specialty section:
This article was submitted to
Neural Technology,
a section of the journal
Frontiers in Neuroscience
Received: 29 June 2015
Accepted: 17 September 2015
Published: 14 October 2015
Citation:
Nafissi N and Foldvari M (2015)
Neuroprotective therapies in
glaucoma: II. Genetic nanotechnology
tools. Front. Neurosci. 9:355.
doi: 10.3389/fnins.2015.00355
Neuroprotective therapies in
glaucoma: II. Genetic
nanotechnology tools
Nafiseh Nafissi and Marianna Foldvari *
School of Pharmacy and Waterloo Institute of Nanotechnology, University of Waterloo, Waterloo, ON, Canada
Neurotrophic factor genome engineering could have many potential applications not
only in the deeper understanding of neurodegenerative disorders but also in improved
therapeutics. The fields of nanomedicine, regenerative medicine, and gene/cell-based
therapy have been revolutionized by the development of safer and efficient non-viral
technologies for gene delivery and genome editing with modern techniques for
insertion of the neurotrophic factors into clinically relevant cells for a more sustained
pharmaceutical effect. It has been suggested that the long-term expression of
neurotrophic factors is the ultimate approach to prevent and/or treat neurodegenerative
disorders such as glaucoma in patients who do not respond to available treatments
or are at the progressive stage of the disease. Recent preclinical research suggests
that novel neuroprotective gene and cell therapeutics could be promising approaches
for both non-invasive neuroprotection and regenerative functions in the eye. Several
progenitor and retinal cell types have been investigated as potential candidates for
glaucoma neurotrophin therapy either as targets for gene therapy, options for cell
replacement therapy, or as vehicles for gene delivery. Therefore, in parallel with deeper
understanding of the specific protective effects of different neurotrophic factors and the
potential therapeutic cell candidates for glaucoma neuroprotection, the development
of non-invasive and highly specific gene delivery methods with safe and effective
technologies to modify cell candidates for life-long neuroprotection in the eye is essential
before investing in this field.
Keywords: neurodegenerative disease, glaucoma, neurotrophic factor therapy, gene and cell therapy,
nanotechnology, minicircle DNA vectors, transposon systems, ZFN- TALEN-CRISPR/Cas
Introduction
Glaucoma is one of the most common causes of blindness in the world with over 70 million people
(79 million by 2020), including 400,000 Canadians, affected by this disease (Foster and Resnikoff,
2005). While preventable with proper diagnosis and continual treatment, a patient’s vision cannot
be recovered once it has been affected. The underlying mechanisms associated with glaucoma
progression are still under investigation, but it is well established that the damage to retinal ganglion
cells (RGCs) is mainly the result of mechanical injury resulting from increased intraocular pressure
(IOP) caused by disruption of the trabecular meshwork (Margalit and Sadda, 2003).
Local vascular insufficiency at the optic nerve head can also lead to a decrease in neurotrophic
factors (NFs) levels (Bessero and Clarke, 2010), which results in RGC death (Fang et al., 2010).
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Currently, glaucoma management relies on pharmacological and
invasive surgical treatments mainly by reducing the IOP, themost
important risk factor for the progression of the visual field loss.
There is strong evidences from several research groups that
repeated administration of neurotrophic factors (NTFs) such
as neurotrophin-4 (NT-4), brain-derived neurotrophic factor
(BDNF) (Di Polo et al., 1998), ciliary neurotrophic factor
(CNTF) (Ji et al., 2004), and glial cell line-derived neurotrophic
factor (GDNF) (Jiang et al., 2007) increased the survival of
neurons in rodent models. Among the NTFs, BDNF appears
to provide the highest level of protection by supporting both
protective and regenerative functions (Danesh-Meyer, 2011).
BDNF has a direct effect on RGCs and appears to correct
problems with bidirectional transport of NTFs and by indirect
influence on other retinal cells, helps direct damaged axons.
Initial damage to axonal transport has already been attributed
to a deficiency in NTFs. For instance, neurotrophin deprivation
due to bidirectional axonal transport obstruction within RGCs
has been shown to result in axonal damage (Iwabe et al., 2007).
Retrograde flow at the optic nerve head prevents proteins made
by RGCs from reaching their axonal extensions and perturbed
retrograde transport of NTFs produced in the superior colliculus
(SC) in the brain to reach the RGCs (Lim et al., 2010). Several
studies have now identified the potential role of astrocytes,
microglia and Müller cells in RGC survival within the optic
nerve head region through their secretion of NTFs (Johnson and
Morrison, 2009). This has been suggested by studies involving
adenovirus-mediated intravitreal delivery targeted towardMüller
cells (Di Polo et al., 1998) and after a single intravitreal injection
of BDNF in a cat model (Weber et al., 2008). The targeting of
regenerative factors to Müller glial cells can also stimulate their
dedifferentiation into multipotent progenitor cells, which may
differentiate into new RGCs or photoreceptor cells to replace the
ones that became damaged during injury by high IOP. BDNF also
appears to support axonal path finding to the brain (Benowitz
and Yin, 2008, 2010).
It is nowwidely recognized that lowering IOP in the treatment
of glaucoma is not enough. In addition to neuroprotective and
neuroregenerative approaches, poly-therapeutic strategies may
be the future. Combination treatments such as IOP-lowering
drugs with neurotrophic factors and/or antioxidants and/or anti-
apoptotic agents may be necessary. The common challenge
to all these therapeutic possibilities lies in the delivery and
maintenance of NTF levels in the retina for a prolonged period.
Neurotrophic factor-based gene therapy may meet this
challenge. It could be performed either by direct transfer of
transgenes coding for NTFs into the patient or by using living
cells that express NTFs persistently as vehicles to transport the
NTF transgenes. In general, gene delivery and prolonged or stable
expression of the intended therapeutic transgenes in target cells
are the key factors to a successful gene therapy approach.
In part I of this paper we discussed the supportive effects of
different NTFs in glaucoma, identified different methods of NTF
transgene delivery, and discussed potential cell candidates for
cell-mediated therapy. Here, we focus the review on advanced
techniques for production of safer and more efficient DNA
vectors as well as innovative non-viral approaches for ex vivo
gene delivery/gene editing in order to provide stable and
long-term expression of therapeutic genes such as NTFs in
suitable candidate cells.
RGC Rescue Therapy in Glaucoma
Treatment
Exogenous supplementation of NTFs, apoptosis inhibitors and
survival factors as transgenes or their recombinant protein
products is a promising approach to stop or decline RGC death
in progressive glaucoma (Thumann, 2012).
Interrupting the apoptosis cascade by delivering genes
encoding caspase inhibitors or expressing anti-apoptotic genes
such as Bcl-2, or interfering with the expression and activity
of pro-apoptotic factors by siRNA technology have been
successfully tested in preclinical studies of glaucoma treatment
in animal models (Liu et al., 2009; Thumann, 2012).
Additionally, increasing NTF levels by gene delivery has been
widely investigated in vitro and in vivo. NTFs are small proteins
that are secreted by the central and peripheral nervous system
and are critical in their own development and maintenance (Lim
et al., 2010). NTFs are classified into several groups and among
them, the nerve growth factor (NGF) family members such as
GDNF, BDNF, NTs, and CNTF have been the subject of more
detailed studies for gene therapy in glaucoma(Johnson et al.,
2011).
NTF supply is important for RGC survival or regeneration
during development, and extensive experimental strategies have
been tested to supply exogenous NTF to protect and promote
survival of injured RGCs in glaucoma.
Although direct gene therapy by delivering the exogenous
transgenes encoding for NTFs using different viral and non-
viral carriers are particularly attractive, in certain cases such as
glaucoma, life-long neuroprotective support through exogenous
NTF therapy is essential. Therefore, cell therapy would be a
more sustainable approach via delivering NTFs by living cells
and direct replacement of growth factors and NTFs by cells
that are genetically modified ex vivo. Application of genetically
modified cells as gene delivery vehicles has certain advantages
such as relative simplicity of manipulation and evaluation of cells
in vitro compared to in vivo gene modification. Furthermore,
some of these modified cells continue to divide in vitro under
certain culture conditions, which facilitates expansion of these
cells for further investigations. Finally, some of these engineered
cells show a tendency to localize into particular tissues.
Recent studies showed that several stem and progenitor
cells expressing and secreting the NTFs provide neuroprotective
support when transplanted into animal models of glaucoma and
other retinal diseases (Johnson et al., 2011). In this paper we
focus on advanced non-viral nanotechnology tools for genetic
modification of candidate cells aiming to achieve long-term
expression of NTFs therapeutics.
New Generation of DNA Therapeutics
The necessity to generate safe and efficient DNA vectors
for transgene delivery via a variety of non-viral approaches
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has spurred many different proposals. Among them bacterial
sequence free DNA vectors in two forms such as supercoiled
circular covalently closed and linear covalently closed DNA,
termed as “minicircle” and “ministring,” respectively, are
considered the most promising (Darquet et al., 1997, 1999;
Chen et al., 2003; Nafissi and Slavcev, 2012; Nafissi et al., 2014;
Slavcev et al., 2014; Slavcev and Nafissi, 2014). Replication and
largescale production of plasmid DNA vectors is dependent
on the prokaryotic backbone and specific selection markers
to isolate and propagate plasmid-containing bacterial strains
after bacterial transformation. However, these sequences are
undesirable in clinical applications because of the following
reasons: (A) the bacterial sequences are recognized as invading
factors and trigger host innate immune response that leads
to systematic removal of the vector (Klinman et al., 1996;
Mitsui et al., 2009); (B) the horizontal transfer (importing
genes from environment or from other bacteria) of antibiotic
resistant genes from plasmid DNA to normal microbial flora
is a risk factor for the generation of antibiotic resistant flora
(Chen et al., 2008); (C) residual selection markers in the
final plasmid product, due to unsuccessful removal, can cause
allergic reaction and hypersensitivity in sensitive individuals
after gene delivery (Cavagnaro, 2013); and (D) the bacterial
sequences are reported as the main cause for heterochromatin-
dependent silencing of the intended transgene (Chen et al., 2003;
Mayrhofer et al., 2009). In contrast, the new generation of DNA
vectors that are bacterial sequence free offer higher and more
persistent expression, generally at levels 100–1000 times greater
than their standard plasmid precursor (Kay, 2011). Previously,
purification of miniDNA vectors from bacterial extracts was
labor-intensive, time-consuming, and a multi-step process that
needed digestion of the bacterial backbone by a restriction
enzyme (Schakowski et al., 2001, 2007) followed by purification
of miniDNA vector and removal of digested sequences by
cesium chloride ultracentrifugation (Bigger, 2001; Chen et al.,
2005). However, employing prokaryotic-derived site-specific
recombination systems, mainly from bacterial viruses (phage)
such as λ integrase (Int), P1-derived, Cre, phiC31Int, N15-
derived TelN, and PY54-derived Tel, dramatically facilitated the
production and purification of miniDNA vectors (Nafissi and
Slavcev, 2014). These systems show limitations that have been
improved over the time (Table 1). In general, the first step in
generating bacterial sequence-depleted DNA vectors with phage-
derived enzymes is to engineer a bacterial cell (mainly E.coli)
that express these enzymes, insert the recognition sequence of
these enzymes in to the plasmid DNA vector closely upstream
and downstream of the therapeutic transgene expression cassette,
and transfer the plasmid into engineered E.coli cell (Nafissi
and Slavcev, 2012). Consequently, the in vivo intramolecular
recombination at the recognition sites results in generation
of two well-characterized molecules from the single parent
plasmid:(i) the miniDNA vector (circular or linear covalently
closed) comprising the therapeutic transgene expression cassette,
and (ii) the miniplasmid containing the bacterial backbone
elements (Figure 1). Combining the endonuclease I-SceI together
with its recognition site in the plasmid backbone allows
simultaneous digestion of the bacterial backbone into small
pieces and production of purified miniDNA vector. For
instance, further purification of the minicircles by affinity-
based chromatography allows the isolation of highly pure and
pharmaceutical-grade minicircles by this technique (Rodríguez,
2004; Thyagarajan et al., 2008). For the first time, Darquet
et al. (1997, 1999) showed that “minicircle” DNA confers
much higher transgene expression levels in vitro and in vivo,
respectively, compared to the parental plasmid precursors
or other conventional control plasmids encoding the same
transgene. This result was further confirmed, and showed an
even more significant increase in the expression of the encoded
transgene, when the same amount (weight-to-weight basis) of
minicircle DNA and parental plasmids were delivered (Darquet
TABLE 1 | In vivo phage-derived systems for production of minicircle DNA vectors.
Phage-derived production
systems
Advantages Limitations Pharmaceutical
scaled production
Phage λ attB-attP recombination Size exclusion/sequence-specific purification;
low recovery due to bidirectional recombination
reaction (Nafissi and Slavcev, 2014)
Not possible
FLP/frt site-specific
recombination
Bidirectional and fully reversible recombination
reaction, results in generation of multimeric
DNA structures (Sadowski, 1986)
Not possible
Cre/mutated loxP site-specific
recombination
Unidirectional recombination reaction, tight control
of recombinase gene expression, generating of
monomeric minicircle molecules (Bigger, 2001)
Size exclusion/sequence-specific purification,
co purification of bacterial sequence is an issue
Not possible
8C31 integrase Unidirectional recombination reaction, tight control
of recombinase gene expression, generation of
monomeric minicircle molecules, in vivo enzymatic
degredation of bacterial sequence results in
facilitated purification, high-yield production of
minicircles (Kobelt et al., 2013)
Not reported Possible
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FIGURE 1 | Schematic representation of the recombinase-mediated production if minicircle DNA vectors. In vivo production of bacterial
sequence-depleted DNA vectors with phage-derived enzymes is processed via insertion of the recognition sequence (attB or loxP site) of recombinase enzymes into
the intended plasmid DNA vector closely upstream and downstream of the therapeutic gene expression cassette. This plasmid is then transferred into the engineered
E.coli cell capable of expressing the recombinase enzyme. Consequently, the in vivo intramolecular recombination at the recognition sites results in generation of two
smaller molecules from the single parent plasmid DNA: (i) the minicircle DNA vector comprising the therapeutic gene expression cargo, and (ii) the miniplasmid
containing the bacterial sequences including the origin of replication and the antibiotic resistant gene.
et al., 1997, 1999; Chen et al., 2003, 2005; Vaysse et al., 2006; Jia
et al., 2010). After developing the convenient production systems
mentioned above, miniDNA vectors have been extensively
studied by different research groups by comparative studies
with the parent plasmids (Table 2). The following examples
reflect the broad applicability of the new generation of
DNA vectors from gene therapy to more recently in stem
cell research and regenerative medicine considering dynamic
aspects from formulations and optimization of miniDNA
vectors complexes with synthetic vectors. Neural stem cells
(NSC) that are very difficult to transfect were successfully
transfected by minicircle DNA vector by microporation and
showed higher transgene expression and NSC survival when
compared to their plasmid counterpart (Madeira et al.,
2013).
Minicircle DNA vectors have been also used as integrating
vectors for recombinase-mediated cassette exchange (RMCE)
(Jakobsen et al., 2013) or as a sleeping beauty transposition
system (Sharma et al., 2013), and minicircles significantly
improved the integration efficacy and genemodification capacity,
respectively, compared to the standard plasmids. In a different
study, same molar ratio and same copy numbers of the
minicircle and plasmid DNA vectors were complexed with
lipid-based nanoparticles and were transfected into a variety
of human cell lines and in animal models. This study
confirmed previous results and showed that transgene delivery
by minicircle DNA vectors significantly improves transgene
expression levels both in vitro and in vivo. This group also
concluded that improved minicircle delivery in vivo and higher
transgene expression levels are due to the compact size of
minicircle-nanoparticles, better cellular uptake and cell entry,
higher intercellular minicircle copy numbers in transfected
cells, better intracellular trafficking toward nuclei, and better
nuclear uptake. These results also showed higher mRNA
transcription levels in minicircle-mediated transgene delivery
compared to parent plasmid-mediated transgene delivery (Kobelt
et al., 2013). They concluded that the euchromatin structure
and more accessibility of bacterial-sequence-free DNA vectors
to transcription machinery of host cell is a key reason for
higher expression level of transgene. Even further modification
of miniDNA vectors to combat intracellular barriers such
as nuclear membrane would dramatically improve transgene
delivery, especially in slow or non-dividing cells. For example
it was shown that the addition of nuclear-targeting sequences
(DTS), such as the SV40 enhancer, or karyopherins (Miller and
Dean, 2009) to the DNA sequence in parallel with removing
undesired bacterial sequences improved transfection efficacy and
expression levels of the transgene and its protein product (Nafissi
et al., 2014).
New generation of DNA vectors represent a promising
alternative to conventional plasmids in terms of biosafety, bio-
and immuno-compatibility, improved gene transfer, potential
bioavailability and cytoplasmic diffusion due to their smaller
size (Nafissi et al., 2014), and low immunogenicity due to the
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TABLE 2 | Features of miniDNA vectors compared to standard plasmid DNA vectors.
General features Plasmid DNA MiniDNA*
Replicative in bacterial host Non-replicative in bacterial host
Supercoiled Supercoiled or circular/linear closed
Bacterial origin of replication No bacterial origin of replication
Bacterial selection marker (Antibiotic resistance gene) No bacterial selection marker (Antibiotic resistance gene)
Relatively high immunostimulatory unmethylated CpG dinucleotides** No to very few immunostimulatory unmethylated CpG dinucleotides
Large-scaled production is available Large-scaled production is available
Pharmaceutical-grade purification is available Pharmaceutical-grade purification is available
Medium to large size*** Relatively smaller than plasmids
*Bacterial sequence depleted.
**Depends to the size.
***Depends to the size of therapeutic transgene.
lack of bacterial sequences and immunogenic motifs (Chen
et al., 2003; Vaysse et al., 2006). Although miniDNA vectors
provide more sustained expression of the transgene relative to
standard plasmid DNA vector, in more rapidly dividing cells
and tissues with higher regenerative capacity, most DNA vectors
become diluted after each mitosis and eventually disappear.
Therefore, permanent introduction of a therapeutic transgene
followed by its sustained expression is more desirable where
life-long pharmaceutical effect is needed. In particular, in the
case of gene or cell mediated therapy of glaucoma and other
neurodegenerative disorders that require life-long and stable
expression of NTFs, tightly controlled integrating DNA vectors
and strategic genetic engineering systems are required (Jandial
et al., 2008; Blurton-Jones et al., 2014). Therefore, better
and safer techniques of genome editing could open a new
avenue to investigate and treat neurodegenerative disorders more
effectively.
Permanent expression of therapeutic genes is generally carried
out by three different approaches: (i) random integration
(illegitimate insertion); (ii) homologous recombination (HR); or
(iii) site-specific insertion of the transgene into the chromosome
of an anticipated cell. Random integration is mostly carried
out by viral vectors to achieve insertion of an exogenous
transgene into the host human cell’s genome. However, lack of
control over the site and position of integration would result in
undesirable side effects such as unpredictable expression level
or silencing of the integrated transgene, potential mutagenesis
of neighboring genes, activating oncogenes/ deactivating tumor
suppressor genes, and eventually cancer. Therefore, random
integration by viral vectors is not a safe method for permanent
and sustained expression of therapeutic transgene in ex vivo cell-
mediated therapies. HR and site-specific insertion are indeed
the methods of choice for the optimal control over the site
of transgene integration, the number of copies inserted per
target cell, the expression level of therapeutic transgene, and
to reduce the risk of oncogenesis. Safe and efficient site-
specific insertion is carried out through bacteriophage integrase-
mediated and transposon systems, and HR through recent and
efficient techniques involving Zinc Finger Nucleases (ZFN),
Transcription Activator-Like Effector Nucleases (TALENs), and
Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR).
Site-specific Recombination for Cell
Therapy
The interest in precise gene modification is growing dramatically
owing to recent advances in targeted genome engineering.
Targeted genetic engineering techniques allow very specific
modifications such as gene insertion, deletion, and replacement.
Permanent modification of cells has been extensively used in
regenerative medicine as a new clinical tool.
Some examples are engineering glial progenitor cells to
permanently express adhesion molecules to increase homing of
these cells into the brain (Gorelik et al., 2012), or enhancing
the therapeutic effects of stem cells by permanent insertion of
NTF genes (Crigler et al., 2006; Janowski and Date, 2011). Here
we briefly review some of the most popular and safe non-viral
methods for genetic engineering of clinically relevant cells and
insertion of therapeutic transgenes such as NTF encoding genes
into anticipated cells by transposon systems and bacteriophage-
mediated integrase systems.
Transposon Systems
Non-viral transposon systems have been widely used to generate
genetically modified and clinically relevant human cells including
but not limited to induced pluripotent stem (iPSC), embryonic
stem cells (ESC), and mesenchymal and hematopoietic stem
cells (Saha et al., 2015). “Sleeping Beauty transposon system
(SBTS)” and “piggyback (PB) transposon system” are the two
transposon systems that have been successfully used as non-
viral gene delivery carriers for gene modification and generation
of clinical grade human cells for gene and cell therapy. These
systems have lower cost for design, construction, and production
of pharmaceutical grade products on a large scale as well as
stimulating low levels of innate immunity and the capacity to
co-deliver multiple therapeutic transgenes compared to viral
integrating systems.
Sleeping Beauty Transposon System
(SBTS)
“Sleeping Beauty transposon system (SBTS)” is a non-viral
plasmid-based integration system that combines the integration
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benefits of viral vectors and ease of production and manipulation
of naked DNA vectors and ease of delivery by nanoparticles.
The SBTS consists of (A) a plasmid transposon carrying
the therapeutic transgene expression cassette flanked by the
terminal Inverted Repeats (IR) that contain binding sites for
the transposase enzyme; and (B) a source of transposase
enzyme, which is a 360-amino acid DNA-binding protein with a
transposon binding domain, a nuclear localization signal (NLS),
and a catalytic domain.
The SBTS systems mostly target the TA rich sites of the
hosting genome to insert the intended therapeutic transgene
expression cargo. The gene encoding for the transposase enzyme
can be assembled either on the same plasmid that express
the therapeutic transgene (sis) or can be located at a different
plasmid (trans). In case of trans expression, the two DNA
vectors (one carries the transposase enzyme encoding gene and
the other carries the therapeutic transgene expression cassette)
could be packed within the same nanoparticle carrier and
co-transferred into the intended host cell. Few hours after
delivery, the transposon system would reach the nucleus of the
host cell, the transposase enzyme would be expressed in the
cytoplasm and the NLS that has been added to its sequence
would direct import of the transposase into the nucleus, cut
the IR sequences, and facilitate relocation and insertion of the
therapeutic transgene expression cargo from DNA vector into
the host genome (Aronovich et al., 2011) (Figure 2). Similar to
other technologies, SBTS system needs to be improved before
entering into clinical trials. For example, in order to achieve
pharmacologically relevant expression level of the therapeutic
gene and just sufficient transposase expression to carry out
the cut-and-paste reaction in difficult-to-transfect target cells,
better delivery techniques are required. In addition, precise
understanding of the target cell genome would assure insertion of
the therapeutic gene into the TA sites and avoids the side effects
of insertion into undesired loci.
Transposase expression level and duration of expression is
critical in transposon systems because very high expression level
of the transposase would cause insertion of the transgene into
many different locations of the hosting genome that are rich in
TA. In addition, long-term expression of the transposase is also
not desirable because it might cause the excision of the integrated
transgene out of genome and reverse the effect. Therefore, a good
understanding of the host’s genetic background, type of tissue
to be targeted, and therapeutic gene vs. transposase expression
level is necessary to improve transposition efficacy (Aronovich
et al., 2011). The CMV promoter would provide a high but
FIGURE 2 | Schematic representation of the non-viral transposon-mediated site-specific gene therapy. The non-viral transposon is used as a
bi-component DNA vector system for delivery and insertion of therapeutic transgenes from a DNA vector into the target cell chromosome. This system is composed
of either one plasmid (cis) or two plasmids (trans) contains the therapeutic gene of interest (GOI) (green arrow) and its expression cargo such as promoter (orange box)
flanked between the two transposon Inverted Terminal Repeats (ITR) (red circles), and the transposase enzyme (blue arrow) expression cargo. (1) After delivery into the
intended target cell and transportation into the nucleus, through a “cut and paste” transposase activity, (2) the transposon is excised from the transposon donor DNA
vector, and (3) the therapeutic transgene is integrated at a chromosomal site.
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short-term expression of the SB transposase enzyme in many
human cells and therefore would inhibit the re-mobilization of
the integrated therapeutic gene after a longer time (Hackett et al.,
2011). On the other hand, tissue-specific mammalian promoters
derive an alternative promoter for the therapeutic transgene for
sustained expression of the transgene in the right site (Kachi
et al., 2006). The SB100X “plasmid-based integrating” transposon
system in combination with electroporation technology (Mátés
et al., 2009) was recently applied to permanently knock-in the
anti-angiogenic and neuroprotective factor PEDF into the ARPE-
19 human retinal pigment epithelial cells under the control of
either CMV or cell specific CAGGS promoters. In this study, the
PEDF positive cells were successfully transplanted into the retina
to treat age-related macular degeneration (AMD) (Johnen et al.,
2012).
As the proof of principle for licensed SBTS technology in
clinical trials it is worth to point out few examples, even though
these trials are not specifically toward the treatment of glaucoma.
(1) In a in phase II clinical trial of cancer immunotherapy
research, patients-derived T cells were genetically modified by
SBTS system to express a chimeric antigen receptor (CAR) and
were injected back to patients with B-cell malignancies in order to
redirect the specificity of human T cells in these patients (Hackett
et al., 2011). (2) SBTS technology provided life-long expression of
Fanc-C and Fanc-A genes to treat Fanconi anemia, or Factor VIII
gene to treat Hemophilia A (Nienhuis, 2008). (3) SBTS-mediated
life-long expression of IL13-HSVTK was achieved to treat brain
tumors (Di Matteo et al., 2012).
In the field of stem cell research, plasmid-based SB systems
have been used in combination with nanoparticles for the
expression of therapeutic genes. For example, four human iPSC
lines were successfully generated and characterized from fetal
fibroblasts using SB-based DNA vector that were combined
and delivered by nanocarriers (Davis et al., 2013). Also, rat
mesenchymal stem cells (rMSCs) were efficiently transfected
by a nanoparticle called “liposome protamine/DNA lipoplex
(LPD).” LPD was electrostatically assembled from cationic
liposomes and an anionic complex of protamine, SB transposon
system, and NLS targeting peptides in order to enhance cell
specific targeting and nuclear uptake. This complex dramatically
improved transposon-mediated gene insertion in MSCs (Ma
et al., 2013). As such, the non-viral DNA-SB-based therapeutics
in combination with engineered cell specific nanoparticles serve
as a promising and long-lasting way to insert therapeutic genes
into the chromosomes of host cells without using a viral
integration systems and their consequent undesirable side effects
(Aronovich et al., 2011).
PiggyBac Transposon System
The PiggyBac (PB) transposon derived originally from
Lepidopterans is composed of two identical short inverted
terminal repeats (700 bp) and a transposase-encoding sequence
(coding a 594 amino-acid transposase). The PB transposase
catalyzes the transposition of the therapeutic gene expression
cargo that is flanked by the inverted terminal repeats carrying
by a plasmid and insertion of therapeutic transgene into
TTAA rich sites of the host genome. The short IR are the key
elements of the PB transposition system (Figure 2). One of
the benefits of PBtransposon system over SBTS is the capacity
of this system to deliver larger transgenes, complex genes,
or multiple therapeutic genes together with their regulatory
regions. However, low transfection efficiency of large plasmids
is still the major limitation of PBtransposon system (Kim
et al., 2011). In terms of safety, one of the concerns about
using PB systems in clinical applications in human cells is
the distribution of over 2000 PB-like elements in the human
genome which raises the risk of genome rearrangement and
the potential for remobilization of the integrated transgene
by endogenous transposase expression. However, recently the
potential undesired PB-mediated genomic rearrangements have
been investigated to determine the safety of PB systems in clinical
applications. No genomic rearrangement and re-mobilization
of the integrated transgene were observed, but it was also
suggested that long-term evaluation of the safety of transposase
systems in animal models is needed to reach a final conclusion
(Saha et al., 2015). Therefore, despite these observations,
insertional mutagenesis in unwanted sites or rearrangement of
the neighboring genes and gene remobilization after integration
of the therapeutic gene into host genome still remains the major
limitation of PB transposon system in the precise modification
of clinically relevant stem/progenitor cells (Li et al., 2013). The
PB system was efficiently applied to reprogram murine and
human embryonic fibroblasts and to generate pluripotent stem
cells. As such, four transcription factors (c-Myc, Klf4, Oct4, and
Sox2) were inserted into the genome of embryonic fibroblast
cells to reprogram them and to generate pluripotent stem cells.
Furthermore, applying the natural tendency of PB transposase
to excise the inserted transposon, transcription factors were
removed from well-established iPSC cell lines (Woltjen, 2009)
post reprogramming. The PB system was also successfully
applied in field of cancer immunotherapy by isolating T cells
from patients with malignancies and generating genetically
modified tumor-antigen-specific T cells. These cells were further
injected to patients and the anti-tumor activity of modified T
cells with one or multiple insertions was evaluated (Nakazawa
et al., 2009). Several studies were carried out using the PB
transposon plasmid DNA vectors combined with polymer- or
lipid-based nanoparticles to enhance transgene delivery and
insertion of the intended gene through PB transposase activity
in mammalian cells (Palavesam et al., 2013; Chakraborty et al.,
2014).
The miniPB system was recently generated and applied to
insert the GOI into the host genome with the same integration
efficiency but using a much smaller plasmid vector with the
advantage of enhanced transfection efficiency in vitro and in
vivo (Solodushko et al., 2014). The mini PB plasmid is a single-
plasmid system (cis) carrying the transposase gene and very
short inverted terminal repeats (35 bp) flanking the therapeutic
transgene expression cassette (Yusa et al., 2009; Li et al., 2011).
Compared to the PB transposon system, the SB100X shows
superior efficacy in most human cells including hematopoietic
cells with lower safety risk of random integration and insertional
mutagenesis (Aronovich et al., 2011). However, for multiple
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therapeutic gene insertion, the PB system remains the method of
choice (Saha et al., 2015).
8C31 Integrase
Site-specific DNA insertion systems are derived from prokaryotes
and unicellular yeasts and a number of them have been exploited
to facilitate efficient DNA exchange in human cells (Nafissi
and Slavcev, 2014). In fact, all site-specific integration systems
typically mediate efficient “cut-and-paste” type of DNA exchange
between recognition sites in the range of 30–40 bp or longer.
Invading bacterial viruses (phage) use this system to integrate
their genome into their bacterial host chromosomes by a reaction
catalyzed by integrase enzymes at short sequences, termed as
the “phage attachment site (attP)” and “bacterial attachment site
(attB)” (Nafissi and Slavcev, 2014). Calos and her colleagues
showed that sequences very similar to wild type attP and attB
sites are available in the human genome and called them as
“pseudo attP” and “pseudo attB,” sites because an exogenous
gene can be integrated specifically into these sites in presence
of a phage integrase (Chalberg et al., 2006). The actinophage
8C31 integrase, discovered in the 1990s, efficiently catalyzes a
site-specific genomic integration between two DNA recognition
(Groth and Calos, 2004) sequences: attB containing DNA vector
and a pseudo attP site within the genome of an anticipated
human cell, leading to permanent transgene expression (Chavez
et al., 2011). Using this system, the insertion of a foreign
DNA such as a therapeutic transgene is characterized by the
following events: (1) recombination occurs at a specific site on
the interacting DNA molecules: DNA vector and hosting cell
genomic DNA; (2) expression and synthesis of the recombinase
enzyme in the host cytoplasm using host protein synthesis
machinery; (3) re-location of the integrase to the host cell nuclei
using nuclear localization signals; (4) strand exchange occurs at
small regions of DNA homology within the recognition sites;
(5) pairing of the interacting insertion sites followed by strand
exchange results in structural intermediates; and (6) resolution
of intermediates followed by strand migration (Groth et al.,
2000) (Figure 3). In the human genome “pseudo attP” sites
show 40% similarity to wild-type attP sequence. In comparison
with the “TA” and “TTAA” rich sequences that are the target
sites for the SB and PB transposon systems, respectively, pseudo
attP are mostly located in transcriptionally active, euchoromatin
sites, and exons with less frequency of introns. 8C31 integrase
provides one-copy integration of the exogenous transgene
per cell without disrupting the endogenous genes. Therefore,
integrase-mediated site-specific gene insertion of transcription
factors offers an alternate method of producing iPS cells without
interfering with endogenous gene functions (Lan et al., 2012).
8C31 integrase-mediated insertion of exogenous gene occurs
at 10-fold higher rates than random integration and often
FIGURE 3 | Schematic representation of the non-viral integrase-mediated site-specific gene therapy. This diagram shows how 8C31 integrase system
benefits in gene therapy. (1) One DNA vector that carries the desired therapeutic transgene expression cargo (promoter, transgene, reporter gene, polyA signal) and
also the attB site that is recognized by 8C31 integrase enzyme and one DNA vector that carries the integrase encoding gene are co-delivered to human target cells.
Both DNA vectors enter nucleus, the integrase is produced in the cytoplasm and redirected to the nucleus. (2) 8C31 integrase enzyme binds as a dimer to the attB
site on the therapeutic DNA vector and bounds at pseudo attP sites present in the human genome. (3) A cut-and-paste recombination reaction occurs at the site of
integration, which results in the insertion of the therapeutic transgene expression cargo into the chromosome of human cells at the pseudo attP site. This process
provides long-term expression of the transgene and production of therapeutic protein in the desired target cells.
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provides higher expression levels than those inserted randomly
into the human genome that possibly causes either silencing,
undesired side effects of over expression of the therapeutic
gene, or oncogenesis/genotoxicity (Nafissi and Slavcev, 2014). In
addition, bacteriophage 8C31integrase catalyzes unidirectional
integration of therapeutic gene into only pseudo attP sites
in the human genome and eliminates the risk of excision of
inserted transgene (Chalberg et al., 2006),which is the most
important advantage of this system over transposon systems.
Transgenic animals generated by 8C31integrase-mediated site-
specific insertion never showed any cancer development (Calos,
2006), or the human ESC that been genetically modified by
8C31 integrase retained their ability to differentiate normally
into all three germ layers (Thyagarajan et al., 2008). In
animal models, for example, hereditary tyrosinemia type I and
muscular dystrophy was treated by 8C31 integrase–mediated
integration of fumarylacetoacetate hydrolase and dystrophin,
respectively. In these studies, plasmid DNA carrying the attB site
and the therapeutic transgene were co-delivered with plasmid
DNA expressing integrase by hydrodynamic tail vein injection
(Held et al., 2005) or intramuscular injection followed by
electroporation (Bertoni et al., 2006).
A comprehensive study confirmed the biosafety of 8C31
integrase-mediated integration of therapeutic transgene into
human umbilical cord lining epithelial cells (CLECs) as source
for several stem-cell like cell types (Sivalingam et al., 2010).
Any plasmid DNA-based integration system can be combined
with synthetic carriers to form nanoparticles that are very
efficient in transfecting human cells and transferring the
DNA cargo into the nuclei. Different studies were carried
out to improve this system. Very recently, Oliveira and
colleagues combined polymer-based nanoparticles with integrase
technology to create 8C31-chitosan-mediated gene delivery and
integration system. They have characterized the nanoparticles
and significantly improved the transfection and integration
efficacy in human embryonic kidney cells. They achieved higher
expression levels of small and large integrated transgenes for
over 10 weeks post transfection (Oliveira et al., 2015). Ease
of transfection into mammalian cells using reliable synthetic
formulations and variety of nanoparticles makes the DNA-
based integrating systems superior compared to their viral
counterparts, in particular in terms of immunocompatibility and
safety with genotoxicity perspective.
Homologous Recombination for Cell
Therapy
Unlike viral vectors that usually integrate into the host
chromosome in an uncontrolled fashion, one of the most
policed methods of genome modification is to insert the
therapeutic transgene into the recognized and desired location
by homologous recombination (Figure 4). HR was defined as
critical process involved in genetic diversity and repair of
DNA double-strand breaks (DSBs) in pro- and eukaryotic
cells (Kakarougkas and Jeggo, 2014). The process of HR
is very important in maintaining the chromosome integrity
and to protect and recover any open ended DNA caused
by environmental assaults or invading DNA. This process
involves the alignment of similar DNA sequences to form a
mobile junction between four strands of DNA, termed “Holiday
junctions,” which are highly conserved in both prokaryotic and
eukaryotic cells. HR needs energy and cofactors from host cells
(Nafissi and Slavcev, 2014) and the presence of DNA DSB in
mammalian cells is the essential step to stimulate HR (West,
2003). The frequency of integration byHR appears to be generally
low, about 10−6, for most mammalian cells, but it was reported
that this can be increased up to 100 fold by making DSBs
at the target site by restriction enzymatic reactions such as
CRISPRs, TALENs, and ZFNs. Some of the drawbacks of HR
system is the general low frequency of HR in mammalian
cells, providing the homology arms in the donor DNA vector
carrying therapeutic gene, and the resources of enzymes to
generate DSB in hosting target sequences (Pan et al., 2013;
Yin et al., 2014b). Their sequence-specific binding modules can
recognize unique nucleotides in the genome along with the
fused endonuclease such as FolK1, Cas9, or ZFN to specifically
induce a double-stranded break (DSB) in the chromosome. All
endonuclease systems introduce DSBs in the target DNA and
lead to recruitment of the cellular repair machinery, which can
drive HR with dramatically higher frequency at the cleavage
site in the presence of complementary sequence arms that are
cloned into HR donor plasmid DNA vectors. These systems
have been applied in repair of damaged DNA, gene disruption,
gene insertion, gene correction and point mutagenesis, and
chromosomal rearrangements (Doudna and Charpentier, 2014;
Kim and Kim, 2014). Advanced genome engineering tools are
now commercially available. For example, the TALENs, ZFNs,
and CRISPR technologies are available from Addgene, Sigma-
Aldrich, and Life Technologies.
Zinc Finger Nucleases
As it was mentioned, the process of HR in human cells is indeed
too inefficient to lead to a reliable therapeutic result and creating
DNA breaks is the key step to increase efficacy of this process.
Therefore, ZFNs have been widely used to create the gene-
specific DNA breaksand enhanced the HR efficacy to several
orders of magnitude (Porteus, 2006, 2008). Zinc Finger DNA
Binding Proteins (ZFPs) are a class of DNA binding proteins that
naturally exist in prokaryotes. Through modification of the DNA
recognition and binding function of ZFPs, it is possible to direct
ZFPs to a target sequence of DNA, which enables the site-specific
localization of the ZFPs in a designated sequence. ZFPs have
been developed to either regulate gene expression by a turning
on and off mechanism, or correct genes using endonuclease
enzymes (Davis and Stokoe, 2010). ZFNs are artificial proteins
composed of a DNA-binding protein and a nuclease protein that
is fused to the first protein. Two ZFNs protein domains are
required to bind to DNA, to dimerize and activate the nuclease
domain, and to create a DSB (Porteus and Baltimore, 2003).
A ZFN subunit encompasses three to six zinc-fingers arranged
in a tandem repeat and a catalytic domain of an endonuclease
enzyme, like FolK1, in such a way that a short linker connects
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FIGURE 4 | Schematic representation of the DNA vector-mediated homologous recombination in mammalian cells. The homologous recombination donor
plasmid DNA vector carries four multiple cloning sites (MCS) to facilitate: (1) sub-cloning and insertion of a therapeutic gene (sub-cloned at MCS3) and it’s promoter
(sub-cloned at MCS2) to a desired site of the host genome via two homology arms (sequences homolog to the insertion site are sub-cloned at the MCS1 and MCS4
flanking the therapeutic gene expression cargo). (2) Non-viral delivery of the HR donor DNA vector into the anticipated cell provides translocation of this vector into the
nuclei. (3) Homology arms facilitate recognition of homolog sequence on the target cell’s genome. (4) HR occurs at the homology sites and the therapeutic transgene
expression cargo would integrate into the host chromosome through HR. Adding the LoxP sites (red triangles) to the HR donor DNA vector would facilitate removal of
homology arms, or other unnecessary sequences, after insertion of the therapeutic cassette into the host genome via expression of the Cre recombinase and its
excision activity on the loxP sites through “Cre/LoxP recombination systems.”
the two domains. At the ZFN target site located at the host
genome, the two ZFN subunits are dimerized and the nuclease
is activated and cuts the DNA. Precise ZFN-mediated gene
targeting involves several steps as follows: (1) identify the full
ZFN-binding site within the target GOI; (2) design a pair of ZFNs;
(3) test the ZFN pair for activity; (4) identify a targeting construct
to create the desired genomic modification; (5) co-transfer the
ZFNs and the targeting vector to create the breaks and to insert
the therapeutic transgene at the target site, respectively (Jamieson
et al., 2003). ZFN derived HR was applied in different clinically
relevant studies. In the field of neuroscience, engineered ZF
protein transcription factors (ZFP TFs) has been used to improve
expression of endogenous glial cell-derived neurotrophic factor
(GDNF) in a rat model of Parkinson disease and resulted in
improved functional neuroprotection in the brain (Laganiere
et al., 2010). Also, Lipofectamine-mediated transfection into
human embryonic kidney cells indicated that ZFNs can be used
to specifically target the ROSA26 safe site of the chromosome
in order to effectively establish new cell lines with predictable
expression level of the desired therapeutic gene (Perez-Pinera
et al., 2012). In a different study, lipid-based nanoparticles were
applied to deliver HR donor plasmids carrying the homologous
sequence to hepatitis B virus (HBV) and specific ZFNs into cells
that have been infected by HBV virus. This study confirmed
the pharmaceutical application of ZFNs toward specific cleaving
the invading virus genome in infected human cells as a new
therapeutic approach (Cradick et al., 2010).
Like any other integrating system, application of ZFNs are
limited to the very precise recognition of the target site and
the homology sequence, precise design and construction of the
appropriate ZFN, risk of non-specific and random binding of
the ZFNs into the undesired sites with similar but not perfect
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homology and consequent integration of therapeutic transgene
into unwanted locations, genotoxicity, and finally, the risk of
leaving open ended double strand breaks and its consequent
risks such as mutation, genome rearrangement, or cell death
(Wirt and Porteus, 2012). Several investigations carried on to
improve the specificity of ZFNs in clinically relevant cells. Some
of these studies applied lipid-based nanoparticles to target cells
and deliver donor DNA vectors to the target site. For example,
a modular assembly technique was described to find the most
effective ZFNs after delivery (Kim et al., 2009), or the “OPEN
(Oligomerized Pool ENgineering)” technology was developed to
construct over 30 highly active and effective ZFN pairs to target
different chromosomal regions in human cells by lipofection
(Maeder et al., 2008; Fu et al., 2009).
TALEN
The TALENs are pre-designed restriction enzymes that are
capable of specific cutting of a desired DNA sequence. However,
similar to ZF or any other nuclease-based insertion method,
customer/project-based design of these restriction enzymes is
necessary and needs precise understanding and computer-based
analysis of the target cell and insertion site because the off-target
cleavage of potential similar sequences causes too much damage
to the host genome and usually cause cell death. Very recently,
applying the “Golden Gate TALEN and TAL Effector Kit” from
Addgene, human embryonic kidney and human iPSC cells were
genetically modified efficiently with TALEN system (Cermak,
2011). The “Golden-Gate assembly system” was developed using
over 400 different plasmid DNA vector carrying TAL effector and
Folk1 encoding genes in order to make a TALEN library. These
plasmids complexed with Lipofectamine or polyethylenimine
were delivered to several human cells to monitor their activity
(Kim et al., 2013). However, similar to ZFN, TAL effector
proteins require protein engineering to bind to a desired DNA
sequence. Other improved system has been introduced by System
Bioscience Company, which facilitates the precise insertion of
the gene of interest into the AAVS1 “safe site” of the human
genome using the TALEN endonuclease technology. The AAVS1
site, located on chromosome 19, is a natural integration hotspot
of Adeno-associated virus (AAV) type 2 (Hüser and Heilbronn,
2003). It was shown that AAVS1 site can be considered as
a safe site for nuclease mediated HR and insertion of the
therapeutic genes for stable and long-term expression (Sadelain
et al., 2012). Recently, ZFNs and TALEN targeted to AAVS1 were
also used to insert therapeutic genes into this location (Figure 5),
such as insertion of the transgene encoding gp91 in iPS cells
derived from patients with X-linked chronic granulomatous
disease and restore the gp91 function. These patients suffer
from defective gp91 expression and are not able to produce
reactive oxygen species (Zou et al., 2011). Insertion of exogenous
gp91 into the AAVS1 site is a novel pharmaceutical approach
to cure this disease. In a different study, the activity of several
exogenous and endogenous mammalian promoters on the
expression levels of the transgenes were investigated applying
plasmid-based TALEN strategy combined with nanoparticle-
mediated transfection to insert promoters for more transient
expression and check expression of the downstream genes over
time (Smith, 2008). More studies on the effect of epigenetic
regulations on transgene expression level, effect of promoter
silencing, and transcription factors have been done using
TALEN technology. For example, TALEN plasmid and transgene
plasmids were delivered into human cells using Lipofectamine
and polyethyleneimine nanoparticles to investigate selective
activation of the endogenous oct4 pluripotency gene via TALEN
technology by activating reprogramming genes and inhibiting
epigenetic factors to generate induced pluripotent stem cells
(iPSCs) from somatic cells (Bultmann et al., 2012).
CRISPR
CRISPR is the name of DNA sites in bacteria containing
short sequences repeated multiple times within the genome of
prokaryotes. These sequences produce adaptive immunity in
bacterial cells against phage and plasmid infections and protect
bacterial cells against invading viruses or foreign plasmids. The
endonuclease encoding locus stores snippets of foreign sequence,
which eventually would be transcribed into RNAs. These RNAs
would be used as a guide based on sequences complementarity
to introduce site-specific double-strand break in the target DNA
or to cleave invading nucleic acids (Doudna and Charpentier,
2014). The endonuclease CRISPR-associated protein Cas9 cleaves
DNA according to the sequence within an RNA duplex and
creates site-specific double-strand break. CRISPRs are often
associated with cas genes which code for endonucleases that
perform various functions related to CRISPRs such as using a
guide sequence within a RNA duplex and aligning it with a target
DNA sequence. Post alignment, Cas9 generates a DSB in the
target DNA, which provides the DNA open ends and initiate non-
homologous recombination or homologous recombination if the
similar sequence has been provided by a plasmid DNA vector
or any other endogenousnucleic acid (Doudna and Charpentier,
2014). Recently, the CRISPR-Cas system has been adapted as a
gene editing technique in mammalian cells by applying a DNA
vector carrying cas genes, therapeutic transgene, and specifically
designed CRISPRs to precisely cut host human cell genomic DNA
at a desired location (Mali et al., 2013). However, for few years
limited progress has been made to improve Cas specificity in
variety of human cells due to target cell genotype heterogeneity.
Unlike other nuclease methods, the CRISPR-Cas system requires
the design and synthesis of a guide RNA that simultaneously
targets multiple genomic sites. In last few years, the CRISPR-Cas
technology in combination with better delivery systems such as
physical methods and more advanced nanocarriers dramatically
improved its specificity and efficacy. The number of publications
that applied this technology to edit the genome of human somatic
cells, stem cells, and iPSC cells has been increased radically and
several companies are offering commercially available kits and
services to assist scientists with multidisciplinary backgrounds
who are interested in applying this technique. The following
are just few examples to demonstrate the increasing popularity
of this technology among clinical and scientific researchers.
CRISPR-Cas system has been used to (A) provide in-depth
understanding of carcinogenesis processes through generating
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FIGURE 5 | Schematic representation of ZFN and TALEN-mediated homologous recombination into AAVS1 safe site of human chromosome. The FokI
endonuclease enzyme derived from the prokaryote Flavobacteriumokeanokoites was found to function as two separate domains - one binds DNA in a sequence
specific manner and one cleaves in a sequence independent manner that is highly specific because it needs dimerization for endonuclease activity on the target DNA.
Therefore, by fusing a FokI monomer to two ZFPs or TALEs, which bind to adjacent sequences at a safe site on the human chromosome such as AAVS1 target site, it
is possible to generate sequence specific DNA nuclease complexes that facilitate selective targeting and homologous recombination within human genomes (Davis
and Stokoe, 2010). (1) Two ZFPs or TALEs are designed to specifically target AAVS1 site in anticipated clinically relevant target cell. These proteins are fused to a FokI
cleavage domain to facilitate their nuclease activity. The ZFN or TALEN are co-delivered with the HR donor plasmid DNA vector into the cell by a non-viral gene
delivery technique to reach the nuclei. (2) Inside the nucleus, ZFNs or TALENs recognize specific DNA sequences on the target cell’s chromosome. (3) Binding of two
ZFNs or TALENs complex to the target site allows FoKI to dimerize. (4) ZFNs or TALENs complex creates a targeted chromosome break at the AAVS1 site of the host
cell, which facilitates HR between the donor DNA vector and homologous sequences. (5) After generating the DNA double strand break, the ZFNs or TALENs
complex disassociate from target DNA. (6) The AAVS1 homology arms subcloned into the HR donor DNA vectors recognize the homolog sequences located on the
host genome. (7) HR-mediated insertion of the therapeutic gene expression cargo occurs at the AAVS1 site of the clinically relevant host cell.
tumor-associated genomic rearrangements by causing DSB and
non-homologous recombination of the DNA open ends (Choi
and Meyerson, 2014; Torres et al., 2014); (B) facilitate systematic
analysis of gene functions in human cells by activation (Cheng
et al., 2013) or inactivation of essential genes for positive or
negative selection (Wang et al., 2014) or genes that play key roles
in cell viability and cancer progression, reprogramming somatic
cells to generate iPSC cells (Shalem et al., 2014), and large-scaled
genetic screening for drug targets (Doudna and Charpentier,
2014); (C) facilitate gene therapy of genetic diseases by correcting
genetic mutations involved in inherited disorders by HR (Wu
et al., 2013); (D) produce genetically engineered animal models
for different human diseases and drug discovery (Ma et al.,
2014; Wang et al., 2014); (E) develop new antiviral treatments
by making DSB in the provirus genomic DNA integrated into
the infected host cell genome and deactivating the viral genes
necessary for pathogenesis or reproduction, reassembly and
release of new viruses (Ebina et al., 2013; Hu et al., 2014); and
(F) facilitate precise ex vivo remodeling of stem/progenitor cells
(Doudna and Charpentier, 2014).
Conclusions
More advanced and safer techniques for genome editing
have many potential applications in further understanding
of neurodegenerative diseases, including (A) generating
new cell lines to study basics of disease progression, cell
growth, and differentiation; (B) screening, identification, and
developments of novel therapeutics and their targets; (C)
generating disease animal models; and (D) developing new
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candidates for cell replacement or cell rescue therapies (Yin et al.,
2014a).
Neurotrophic factor therapeutic genome engineering is a
highly coveted clinical aspiration of glaucoma therapy, but only
recent technological advances in improved delivery techniques,
the new generation of bacterial sequence-depleted DNA vectors
carrying only the desired therapeutic transgene expression cargo,
and the availability of modern genome editing techniques could
provide the necessary tools for the modification of complex
genomes and gene therapy in a targeted fashion. We previously
highlighted the rationale for NTFs and their transgene delivery
into cell candidates and discussed the significant effects of
several NTFs on the support and protection of retinal cells
and other cell candidates that might be potential therapeutic
options for glaucoma neuroprotective gene therapy (Nafissi
and Foldvari, 2015). Here, we highlighted the rationale of
genetic modifications for glaucoma therapies either as the gene
therapy targets or cell replacement therapy to provide long-
term neurotrophin therapeutics on-site using new generations
of safer and more efficient DNA vectors and modern genetic
modification techniques.
In general, compared to cell replacement therapies to replace
and integrate functionally active stem/progenitor cells into the
retina, it was shown that cell-based neuroprotective therapies by
prolonged secretion of NTFs is a more straightforward strategy
to nourish and support dying RGCs in progressive glaucoma. In
addition to supplying NTFs, cell-based neuroprotective therapies
may also be able to promote RGCs survival directly through
modifying gene expression in surrounding cells to enhance NTFs
expression on-site (Madhavan et al., 2008). Genetically modified
retinal progenitor cells, that express and secrete the NTFs, have
been shown to provide neuroprotective support to degenerated
or injured RGCs similar to the supportive role of NTFs expressing
NSC or mesenchymal stem cells (MSCs) in regeneration of
neurons (Akerud et al., 2001; Nomura et al., 2005; Zhu et al.,
2005).
Thus, geneticallymodifiedNTFs secreting cell-based therapies
provides new avenues to fight with the irreversible loss of RGCs
associated with glaucoma. Currently we have efficient tools for
permanent, reversible, or conditional genetic manipulations of
almost any type of cells. The success of clinical trials in other
disorders gives rise to similar approaches in the context of
neurodegenerative diseases including glaucoma. Ultimately, a
better understanding of cell development and stem cell biology at
the molecular level, along with improvements in the techniques
for non-viral gene delivery, advances in nanotechnology and
nanomedicine for synthesis of more cell-friendly structures,
and in-depth knowledge of gene modification systems at the
molecular level would encourage scientists to develop novel
treatments for degenerative disorders. Non-viral gene delivery
techniques such as electroporation (Helledie et al., 2008)
nucleofection (Dwivedi et al., 2012; Madeira et al., 2013), as well
as nanotechnology tools such as application of polysaccharide
nanoparticles (Deng et al., 2013), cationic liposome nanoparticles
(Madeira et al., 2010), calcium phosphate nanoparticles (Cao
et al., 2011), and nanoneedles (Nakamura et al., 2002), in
parallel with efficient and safe therapeutic transgene insertion
techniques such as 8C31 integrase, transposons, and ZFN,
TALEN, or the CRISPR/Cas9 nuclease systems (Gaj et al., 2013),
are new tools for developing clinically approved cell-based
therapeutics for neurodegenerative disorders like glaucoma.
These systems are more reliable since they avoid the high
risks associated with using viral vectors such as insertional
mutagenesis and undesired immune rejection, provide life-long
therapy by more policed insertion of the therapeutic gene
into the desired site, target a broader range of disorders due
to their capability to accommodate genes of different sizes,
and finally, provides higher activity owing to their ability to
target hard- to-transfect human cells. Before ex vivo modified
cells can achieve therapeutic efficacy for clinical glaucoma
treatment in human, many limitations remain to be overcome.
A reliable and expandable source of retinal cells must be
isolated, expanded, characterized and established. These cells
must demonstrate appropriate engraftment within the retina.
Even with the aforementioned challenges, the in vitro, ex
vivo, and pre-clinical support for genetically modified cell-
mediated RGC repair is undeniable, and warrants the kind
of robust investigation that is currently under way. These
methods, if successful in human trials, could offer several
advantages over traditional pharmacological approaches. While
much work remains to address the safety issues for all of
the above mentioned approaches, evidently, this is a multi-
disciplinary field which undeniably needs collaboration from
different scientific domains to bring the bench results to the
clinic.
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